Table 4.

Unadjusted and Adjusted Outcomes for Length of Stay and Hospital Costs in the Propensity Score Matched Group

	Alvimopan		Unadjusted differences*	Adjusted differences†
	No	Yes
Length of stay, d [95% CI]‡	6.9	5.5	−1.4 [−0.9, −1.8]	−1.4 [−1.7, −1.0]
Costs, USD [95% CI]§	$12,228	$11,258	−$969 [−$2,253, +$314]	−$1,720 [−$2,456, −$984]

^*Comparison of patients who did and did not receive alvimopan using 2 sample t test.

^†Adjusted using the generalized estimating equations model to account for correlated data at the hospital level.

^‡Length of stay defined as time from surgery to discharge.

^§Hospital costs from the payer perspective.